Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 5Phase 4 2Phase 1 1

Status

Completed 4Recruiting 1

Sponsor Class

OTHER 17INDUSTRY 5UNKNOWN 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1

Conditions

Vomiting 2Neoplasms 1Nausea With Vomiting Chemotherapy-Induced 1Nausea 1Multiple Myeloma 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Palonosetron × Clear all
NCT06904235 2026-06-01

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

Helsinn Healthcare SA

Phase 2 Recruiting
95 enrolled

Nausea, Vomiting

NCT04592198 2025-03-24

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

Xiamen LP Pharmaceutical Co., Ltd

Phase 2 Completed
22 enrolled 8 charts

Nausea With Vomiting Chemotherapy-Induced

NCT03204279 2024-06-25

CINV

Helsinn Healthcare SA

Phase 2 Completed
67 enrolled 12 charts

Vomiting

NCT00306735 2016-12-05

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Eisai Inc.

Phase 2 Completed
75 enrolled
Plasma cell

Multiple Myeloma

NCT01909856 2015-12-04

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
92 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡